Fig. 2From: Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannotKaplan Meier survival analyses (truncated at 6Â years) for recurrence-free interval according to tamoxifen treatment in patients with a tumor with low mitotic count (a) and high mitotic count (b)Back to article page